Advertise With Us
Subscribe to Newsletter
IB-Logo

[email protected]

  • Markets
  • Business & Finance
    • Forex
    • Stocks
  • Finance
  • Economy
  • Politics
  • Real Estate
  • Crypto
  • AI
  • Health
  • Research
  • Sports
  • More
    • Tech
    • Science
    • Weather
  • Markets
  • Business & Finance
    • Forex
    • Stocks
  • Finance
  • Economy
  • Politics
  • Real Estate
  • Crypto
  • AI
  • Health
  • Research
  • Sports
  • More
    • Tech
    • Science
    • Weather
IB-Logo
Advertise With Us
Subscribe to Newsletter
  • Markets
  • Business & Finance
    • Forex
    • Stocks
  • Finance
  • Economy
  • Politics
  • Real Estate
  • Crypto
  • AI
  • Health
  • Research
  • Sports
  • More
    • Tech
    • Science
    • Weather
  • Markets
  • Business & Finance
    • Forex
    • Stocks
  • Finance
  • Economy
  • Politics
  • Real Estate
  • Crypto
  • AI
  • Health
  • Research
  • Sports
  • More
    • Tech
    • Science
    • Weather

HIV Cure in Sight

Thomas by Thomas
December 9, 2025
in Research
0
HIV Cure in Sight

The elusive HIV cure inches closer in 2025, with clinical breakthroughs illuminating paths to sustained viral control without lifelong antiretrovirals. A UCSF-led study reveals experimental immunotherapy enabling seven of ten participants to maintain undetectable HIV levels post-treatment cessation, one sustaining remission for over 18 months—offering a blueprint for scalable functional cures. This regimen, blending broadly neutralizing antibodies (bNAbs) like teropavimab and zinlirvimab with lenacapavir, achieved Breakthrough Therapy Designation from the FDA, accelerating Phase 3 trials for twice-yearly dosing that could suppress reservoirs in diverse populations.

Gilead’s CROI 2025 presentations spotlight lenacapavir’s dual role: as a capsid inhibitor yielding near-100% PrEP efficacy in PURPOSE trials, now endorsed by WHO for biannual injections in high-burden regions like Eswatini and Zambia, targeting 2 million doses by 2028. Complementing this, a Nature study documents the seventh cure via heterozygous CCR5Δ32 stem cell transplant, sustaining remission sans ART and underscoring CCR5-independent mechanisms for broader applicability beyond elite controllers.

Case Western Reserve’s revelation of HIV’s dormancy tactic—inducing cellular senescence to evade detection—unlocks “shock-and-kill” refinements, where reactivating latent proviruses triggers apoptosis in infected cells, slashing reservoirs in preclinical models. BioNTech’s mRNA strategies and CRISPR edits further personalize remission, with pharmacogenomics tailoring regimens to genetic profiles for minimized side effects. Amid 1.3 million new infections annually, these advances—fusing antibodies, capsids, and genomics—signal a pivotal shift: functional cures within reach by decade’s end, potentially eradicating AIDS as a public health threat.

RelatedPosts

Outlook Outage Hits NZ With 1,400 Reports: Key Updates
Research

Office Mandate Warning: 76% of NZ Tech Workers Would Say No

November 14, 2026
Outlook Outage Hits NZ With 1,400 Reports: Key Updates
Research

Bitcoin Bottom at $68K? Key Support Tested as Price Falls 6%

November 14, 2026
Outlook Outage Hits NZ With 1,400 Reports: Key Updates
Research

Outlook Outage Hits NZ With 1,400 Reports: Key Updates

November 14, 2026
Research

NZ Millionaires: 980 People Earn $1m+ a Year, IRD Shows

November 13, 2026
Research

New York Marathon Kiwi Goes Viral With Mid-Race Dance

November 13, 2026
Research

NZ Political Donations: National and ACT Lead Funding

November 13, 2026

Facebook

IB-Logo

Latest News & Updates
Premier source for business,
financial news, analysis and insights.

Advertise With Us
  • About Us
  • Contact Us
  • Privacy Policy

© All Rights Reserved 2026 InvestorBytes.

No Result
View All Result
  • About Us
  • Coming Soon
  • Contact Us
  • Main Page
  • Privacy Policy
  • Sample Page

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.

Advertise With Us

I don’t want startup news.

Catch up with Startups Weekly

Your weekly dose of startup insights and innovation, delivered right to your inbox.

I don’t want startup news.